Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases.
Saved in:
| Title: | Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases. |
|---|---|
| Authors: | Davies LC; NextCell Pharma AB, Huddinge, Sweden; QVance AB, Huddinge, Sweden; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. Electronic address: Lindsay.davies@nextcellpharma.com., Biard L; INSERM U1342, Team ECSTRRA, Paris, France; Université Paris Cité, Paris, France; Department of Biostatistics and Medical Informatics, Assistance Publique Hôpitaux de Paris, Paris, France., García-Olmo D; Department of Surgery, Fundación Jiménez Díaz University Hospital, UAM, Madrid, Spain., Gilkeson G; Medical University of South Carolina, Charleston, South Carolina, USA., Gnecchi M; Department of Molecular Medicine, Unit of Cardiology, University of Pavia, Pavia, Italy; Cardiothoracovascular Department, Translational Cardiology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Kurtzberg J; Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA., Kogler G; Institute for Transplantation Diagnostics and Cell Therapy, Düsseldorf, Germany., Blanc KL; Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; Department of Cell Therapies and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden., Lowdell MW; Department of Haematology, University College London, London, UK., Pers YM; IRMB, University of Montpellier, INSERM, CHU Montpellier, Montpellier, France; Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Department of Rheumatology, Lapeyronie University Hospital, Montpellier, France., Sun LY; Department of Rheumatology and Immunology, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China., Tarte K; UMR U1236, INSERM, Univ Rennes, Etablissement Français du Sang, Immunology and Cell Therapy Lab, Rennes University, Rennes, France; SITI Laboratory, CHU Rennes, Etablissement Français du Sang, Rennes, France., Uccelli A; Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Italy., Sanchez-Guijo F; University of Salamanca, IBSAL-University Hospital of Salamanca, Salamanca, Spain., Farge D; Université Paris Cité, Paris, France; Department of Internal Medicine, CRMR MATHEC, Maladies Auto-Immunes et Thérapie Cellulaire, Centre de Référence des Maladies Auto-Immunes Systémiques Rares d'Ile-de-France, FAI2R, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France; Department of Medicine, McGill University, Montreal, Quebec, Canada. |
| Corporate Authors: | ISCT Educational Course Working Group on the Use of Mesenchymal Stromal Cells for Autoimmune Diseases (Paris 2024) |
| Source: | Cytotherapy [Cytotherapy] 2025 Nov; Vol. 27 (11), pp. 1326-1337. Date of Electronic Publication: 2025 Jul 12. |
| Publication Type: | Consensus Statement; Guideline; Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 100895309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-2566 (Electronic) Linking ISSN: 14653249 NLM ISO Abbreviation: Cytotherapy Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
